MINNEAPOLIS, MN, Sept. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of biomedical therapeutics for equines and companion animals, was recently featured in the Sight & Sound's Visionaries Series on Bloomberg Television.
The episode spotlighted PetVivo’s flagship product, Spryng™ with OsteoCushion™ Technology, a revolutionary veterinary medical device that is transforming joint health for animals nationwide.
The unique injectable medical device has garnered widespread attention for its effectiveness in the management of osteoarthritis and other musculoskeletal conditions that contribute to animal lameness.
By mimicking the composition and function of natural joint cartilage and subsynovial tissue, SPRYNG™ offers a highly effective, drug-free option for veterinarians seeking long-term solutions that improve the quality of life for pets.
After airing on September 5, the Visionaries episode was distributed across New to the Street’s digital platforms, including its YouTube channel with 1.4 million subscribers, as well to its 300,000+ social media followers on Twitter, LinkedIn and Instagram.
The program provides insights for investors, stakeholders, and veterinarians into how PetVivo’s innovative solutions has positioned the company as a leader in the growing veterinary medical device industry.
Visionaries takes viewers inside PetVivo's Minnesota R&D laboratory, where PetVivo CEO, John Lai, along with leading scientists and veterinary experts, provide an in-depth exploration of the advanced science behind Spryng with OsteoCushion™ Technology and its transformative impact on animal joint health.
“Spryng™ has redefined how veterinarians approach joint health,” noted Lai, “making it increasingly important to bring our story to a greater national audience. By creating broader awareness of the use and multiple benefits of Spryng, we hope to accelerate the market adoption of this breakthrough product which has already made a major impact on the health and wellbeing of thousands of equine and companion animals.”
The Visionaries episode may be viewed in its entirety on the PetVivo website by clicking here.
PetVivo recently achieved major milestones with Spryng now used by more than 800 veterinary clinics across 50 states and this resulting in the distribution of more than 10,000 Spryng syringes nationwide since first commercialization.
The increasing success of Spryng™ also reflects the fast growing U.S. animal health market, which is projected to double to $11.3 billion by 2030.
For more information about PetVivo and Spryng, please contact info1@petvivo.com or visit petvivo.com and sprynghealth.com.
For more information, visit www.petvivo.com or contact Ron Both of CMA at (949) 432-7557 or submit your request here.
About PetVivo Holdings
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW) is a biomedical device company focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The company is pursuing a strategy of developing and commercializing human therapies for the treatment of companion animals in capital and time efficient ways. A key component of this strategy is an accelerated timeline to revenues for veterinary medical devices that can enter the market much earlier than more stringently regulated human pharmaceuticals and biologics.
PetVivo has developed a robust pipeline of products for the medical treatment of animals and people, with a portfolio of 21 patents that protect the company's biomaterials, products, production processes and methods of use. The company’s commercially launched flagship product, Spryng™ with OsteoCushion™ Technology, is a veterinarian-administered, intra-articular injectable designed for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses.
For more information about PetVivo and its revolutionary Spryng with OsteoCushion Technology, email info1@petvivo.com or visit petvivo.com or sprynghealth.com.
Disclosure Information
PetVivo uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company’s Investor Relations website, in addition to following the company’s press releases, SEC filings, public conference calls, presentations and webcasts.
Forward-Looking commercial Statements
The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
Investor Contact
Ronald Both or Grant Stude
CMA Investor Relations
Tel (949) 432-7566
Email contact
